Sionna Therapeutics, Inc. business relationships
Companies named in Sionna Therapeutics, Inc.’s 10-K filed 2026-03-02, and public companies whose annual reports name Sionna Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.7 / 10
- AI naming
- 4 / 100 Top 3% in its category
- Agent readiness
- 35 / 100
- AI adoption
- 0 / 100
Named in Sionna Therapeutics, Inc.’s annual report 4
“In particular, we have entered into license agreements with Sanofi and AbbVie, pursuant to which, among other things, we have secured exclusive licenses for certain intellectual property and know-how relating to CFTR modulator therapies to commercialize certain compounds, patents and proprietary inf...” SEC filing
“In the event the AbbVie License Agreement is terminated, we and AbbVie shall agree upon a transition plan to revert the licensed compounds or licensed products containing such licensed compounds to AbbVie.” SEC filing
“SION-3067 is a clinical-stage potentiator of CFTR gating activity that we have licensed from AbbVie.” SEC filing
“...re developed by or on behalf of Galapagos and are sublicensed to us subject to the terms of the second amended and restated collaboration agreement between Galapagos and AbbVie in October 2018 (the "Galapagos License Agreement"), as amended by a side letter between Galapagos and AbbVie in July 2024.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.